Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

UPDATE: BioCorRx Announces Distribution Deal with CereCare, LLC for the BioCorRx Recovery Program


Posted on: 12 Dec 17

ANAHEIM, CA , Dec. 12, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addiction, today announced that CereCare, LLC, a company focused on facilitating the provisioning of leading edge treatment solutions to those suffering from substance use disorders and other brain related conditions, is going to become a strategic partner for the BioCorRx Recovery Program. As part of the agreement, CereCare and its principal backers will pay an upfront fee of $100,000 and receive restricted shares in BioCorRx plus performance-based options for reaching certain milestones. CereCare will have exclusive distributorship rights for the BioCorRx Program in Nevada, subject to certain performance criteria.

CereCare establishes and operates medical clinics under its CereCare – Center of Excellence™ brand that focuses on treating alcohol and opiate addictions, as well as other substance use disorders. CereCare operates clinics in Los Angeles, Sherman Oaks, California and Reno, Nevada with plans to open additional locations in Beverly Hills and Palm Springs, California, as well as upstate New York and Ft. Lauderdale, Florida. CereCare will offer the BioCorRx Recovery Program in these clinics.

Brady Granier, CEO, President, and Director of BioCorRx, stated, “We have been working with CereCare since we announced the Serrano Kidney and Vascular Access Center would be the first clinic offering our program to the Hispanic market in Los Angeles, California. We believe CereCare is the perfect partner to become an authorized distributor of our program because they have seen the positive results of our program on patients and we also feel that they have the resources and experience to take this to another level. We will be supporting them in rolling out our program into their clinics and look forward to building out a successful partnership.”

Walter Marting, Managing Member of CereCare, stated, “We are pleased to be a strategic partner for the BioCorRx Recovery Program.  We believe that the combination of BioCorRx Cognitive Behavioral Therapy (CBT) and the naltrexone implant is the best treatment modality for people who have opioid or alcohol use disorders.  We are also in discussions with two major hospital groups and several large self-insured groups about offering this comprehensive treatment and recovery program to their patient and employee populations and covering the costs associated with the program. Our partners within CereCare have deep experience in the health care insurance and re-insurance industries and in establishing Centers of Excellence.”

About CereCare, LLC

CereCare, LLC is a Nevada corporation focused on facilitating the provisioning of leading edge treatment solutions to those suffering from substance use disorders and other brain related conditions. The company has teamed with leading scientists nation-wide to develop these treatment modalities, which uniquely focus on dysfunctional brain conditions and the pathways to treating these brain diseases.

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.


CONTACT: BioCorRx Inc. investors@BioCorRx.com 714-462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 bicx@crescendo-ir.comGlobeNewswire
globenewswire.com

Last updated on: 13/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.